Wikipedia:Version 1.0 Editorial Team/Pharmacology articles by quality log

This is a log of operations by a bot. The contents of this page are unlikely to need human editing. In particular, links should not be disambiguated as this is a historical record.

May 4, 2024[edit]

Renamed[edit]

Drug-naïve renamed to Drug naïvety.

Assessed[edit]

BPOM (talk) assessed. Quality assessed as Redirect-Class. (rev · t) Importance assessed as NA-Class. (rev · t)
Drug naïvety (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)
Indonesian Food and Drug Authority (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Vebreltinib (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

May 3, 2024[edit]

Reassessed[edit]

Vonoprazan (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)

Assessed[edit]

10-Hydroxyketotifen (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Gumarontinib (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Methylenedioxynitazene (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

May 2, 2024[edit]

Reassessed[edit]

N-0385 (talk) reassessed. Importance rating changed from Unknown-Class to Low-Class. (rev · t)

Assessed[edit]

Maxacalcitol (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

Removed[edit]

Draft:Absci (talk) removed.
Draft:ISA Pharmaceuticals B.V. (talk) removed.

May 1, 2024[edit]

Renamed[edit]

Xolremdi renamed to Mavorixafor.

Reassessed[edit]

Carvedilol (talk) reassessed. Quality rating changed from Start-Class to C-Class. (rev · t)
Deuremidevir (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
Grape seed extract (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
Mavorixafor (talk) reassessed. Importance rating changed from Low-Class to Mid-Class. (rev · t)
Pimobendan (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t) Importance rating changed from Unknown-Class to Mid-Class. (rev · t)
Vadadustat (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)

Assessed[edit]

CYB210010 (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

Removed[edit]

Bisin (talk) removed.

April 30, 2024[edit]

Reassessed[edit]

GTPgammaS (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
Phenazone (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)

Assessed[edit]

CRLX101 (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Pexastimogene devacirepvec (talk) assessed. Quality assessed as C-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Proctosedyl (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Xolremdi (talk) assessed. Quality assessed as Redirect-Class. (rev · t) Importance assessed as Mid-Class. (rev · t)

April 28, 2024[edit]

Reassessed[edit]

Cardiac glycoside (talk) reassessed. Quality rating changed from Start-Class to C-Class. (rev · t)

Assessed[edit]

Bradykinin (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Dibutyrylmorphine (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)